INFO sur L'ACCES AUX MEDICAMENTS et LA SANTE

Dernières informations et nouvelles sur la santé et l'accès aux médicaments de qualité.

1201 NEWS on HEALTH and MEDICINES - JANUARY 2012

1110 NEWS ON MEDICINES and HEALTH - SEPTEMBER - OCTOBER 2011

1106 NEWS ON HEALTH AND MEDICINES - JUNE 2011

1105 NEWS ON MEDICINES and HEALTH - May 2011

1104 NEWS ON MEDICINES and HEALTH - April 2011

1103 NEWS on MEDICINES and HEALTH - March 2011

110309 Free malaria treatment

Each year, there are more than 225 million cases of malaria around the world, of which nearly 1 million are fatal, 90% of them in Sub-Saharan Africa where children and pregnant women are the main victims. In recent years the opportunities for fighting and containing malaria have increased. The Global Fund has offered free malaria treatments to many countries in Africa. The resistance problem has been solved by changing to artemisinin-based combination therapies (ACT) in most sub-Saharan  African countries. 

Read more …

110301 Debate on Access to Medicines and Biodiversity at the WTO

On 1st march WTO members debated how current global intellectual property rules affect access to medicine and biodiversity protection, but made little progress on either issue, both of which are priorities for developing countries. The WTO-TRIPS Council discussed the use of a system intended to smooth poor countries’ access to patented drugs, as well as whether WTO rules need to be amended to require patent applicants to disclose the use of any genetic materials in an invention to prevent biopiracy.

Read more …

NEWS on MEDICINES and HEALTH - February 2011

PROGRESS in the ACESS to ESSENTIAL QUALITY MEDICINES in 2010

1101 NEWS on MEDICINES and HEALTH - January 2011

NEWS on MEDICINES and HEALTH - December 2010

NEWS on MEDICINES and HEALTH - November 2010

Health and Access to Quality Medicines July 2010

Access to essential medicines far from being achieved

Access to essential medicines, especially for the poor has not yet become a reality. There are more than 20,000 pharmaceutical products registered in the market - but why do we say that people, especially the poor, cannot access the medicines they need?

Read more …

India Expands Role as Drug Producer

 

India’s drug industry is on track to grow about 13 percent this year, to just over $24 billion.Business is so brisk that Sun, with revenue of 41 billion rupees ($880 million) last year, predicts sales will grow 20 percent this year and is expanding its Halol factory.

Read more …

African Union (AU) meets to find solutions to maternal and child deaths

President Korom - African Union  

This year’s African Union summit, to be held in Kampala will take maternal and child health as its theme. While target four and five of the Millennium Development Goal (MDG) aim at reducing by two-thirds the number of mothers and children who die every year during child birth and childhood illness, many countries are nowhere near meeting that target. African women still die in great numbers while giving birth.

Read more …

Anti-Counterfeit Deal Threatens Accessibility of Drugs

ACTA

A proposed anti-counterfeit trade deal (ACTA) between 10 countries and the European Union (EU) could create a new set of barriers to the export of generic medicines to low income countries. ACTA is aimed at tackling the trade in fake and those infringing on intellectual property (IP) rights by strengthening powers of customs officials in signatory countries to seize counterfeit goods.

Read more …

Most paediatric fevers not caused by malaria

Mother with sick child  

More than half the paediatric fevers treated in public health clinics in Africa are caused by diseases other than malaria, according to a study by Oxford University and other research groups, whose authors caution against the "continued indiscriminate use of anti-malarials for all fevers across Africa." 
Of the 183 million children with malaria symptoms treated by public health clinics in 2007, only 43 percent were diagnosed with malaria, but many more most likely received anti-malarial medication.

Read more …

101109 CONGO - Polio cases confirmed

At least 94 people have died, with 201 cases of acute flaccid paralysis reported in the Republic of Congo (ROC), since 5 November. Four cases have been confirmed as wild poliovirus type 1, says the UN World Health Organization (WHO). This is due to the fact that for the last 15 years, immunization campaigns have not been carried out due to the country's political instability.

tl_files/aefjn-images/1pdficon_sm.jpg101109 CONGO - Polio cases confirmed

Read more …

101104 EU deal threatens HIV drug supplies

In a decade and a half since being diagnosed with HIV, Gangte, a 43 year-old living in New Delhi, has seen his illness transform from a death sentence into a manageable condition, thanks largely to the availability of cheap medicines produced in India... Seven years later, he says he is coming to terms with a new threat to his health: an international trade agreement being brokered between the European Union and India that medical experts warn could leave millions of HIV sufferers in developing world without the drugs they need to stay alive.

tl_files/aefjn-images/1pdficon_sm.jpg 101104 EU deal threatens HIV drug supplies

Read more …

101021 Industry worried by WHO plans to evaluate active ingredients

WHO is starting a pilot where it will prequalify selected APIs because the globalisation of drug production has made it difficult to verify their quality. However, the pharmaceutical industry is concerned the pilot may increase company costs while a US think tank is worried it may take away from the WHO's core business.

tl_files/aefjn-images/1pdficon_sm.jpg101021 WHO plans to evaluate raw materials prompt industry cost worries

Read more …

Factory closure could leave 7,000 babies without ARVs

Pharmaceutical giant Bristol-Myers Squibb (BMS), which owns the French factory that produces didanosine, a second-line ARV for babies weighing less than 10kg, will shut down the plant in June 2010, stopping production of the drug until at least February 2011, when regulatory approval of a new United States-based manufacturing site is expected. Closing this factory means that 4,000-7,000 babies currently enrolled in treatment plans in developing countries through UNITAID [a funding mechanism for HIV treatment] could be left without the medicines they need.

tl_files/aefjn-images/1pdficon_sm.jpgFactory closure could leave 7,000 babies without ARVs

Read more …

Seven Challenges in Development Aid for Health

This paper outlines seven challenges in development assistance for health, which in the current financial context, have become even more important to address. The paper then provides three suggestions for ways forward: - creating new mechanisms to hold donors to account, - developing national plans and - strengthening national leadership in health, and South-South collaboration……”

tl_files/aefjn-images/1pdficon_sm.jpg Seven Challenges in Development Aid for Health

Read more …

100903 Addressing Counterfeits without Endangering Public Health

The actual root of the counterfeit medicines problem is grounded in issues of public health, safety and quality. This is where the attention should be focused: to fix the reality of substandard and adulterated medicines. However, rather than developing the solution from a public health and regulatory angle, countries are using an ‘IP enforcement’ approach.

Read more …

100914 Tougher intellectual property rules may harm trade in medicines

Free Trade Agreements could harm India's generic drug business, which supplies the bulk of the AIDS medicines sent to developing countries. India's generics could cost more and be harder to access if the country has to adhere to stricter intellectual property rules.

Read more …

Update on Medicines and Health - July 2010